Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also dev… Read more
Opus Genetics, Inc. (IRD) - Total Liabilities
Latest total liabilities as of September 2025: $30.16 Million USD
Based on the latest financial reports, Opus Genetics, Inc. (IRD) has total liabilities worth $30.16 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Opus Genetics, Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Opus Genetics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Opus Genetics, Inc. Competitors by Total Liabilities
The table below lists competitors of Opus Genetics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Guanghua Technology Co. Ltd. A
SHE:001333
|
China | CN¥1.09 Billion |
|
Smart Eye AB (publ)
PINK:SMTEF
|
USA | $444.55 Million |
|
Tongling Jieya Biologic Technology Co. Ltd.
SHE:301108
|
China | CN¥330.27 Million |
|
Ascom Holding AG
OTCGREY:ACMLF
|
USA | $118.30 Million |
|
Karsan Otomotiv Sanayii ve Ticaret A.S
PINK:KRSOF
|
USA | $13.98 Billion |
|
Designer Brands Inc
NYSE:DBI
|
USA | $1.75 Billion |
|
YSB Inc.
F:B1S
|
Germany | €4.50 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Opus Genetics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Opus Genetics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Opus Genetics, Inc. (2019–2024)
The table below shows the annual total liabilities of Opus Genetics, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $30.14 Million | +645.62% |
| 2023-12-31 | $4.04 Million | +46.82% |
| 2022-12-31 | $2.75 Million | -28.59% |
| 2021-12-31 | $3.85 Million | -87.62% |
| 2020-12-31 | $31.15 Million | +233.36% |
| 2019-12-31 | $9.34 Million | -- |